Linked research, clinical, and regulatory source pathways.
Company profile
About Pear Therapeutics
Pear Therapeutics was a digital therapeutics company that developed prescription software applications to treat serious mental health and substance use disorders. The company pioneered the prescription digital therapeutics (PDT) category, creating evidence-based mobile interventions that were authorized by the FDA as medical treatments. Pear's products combined cognitive behavioral therapy, contingency management, and other therapeutic modalities with digital delivery to provide accessible, scalable treatment options. The company's flagship products included reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for chronic insomnia. These applications were designed to be prescribed by healthcare providers and used by patients as standalone treatments or adjuncts to traditional care. Pear Therapeutics filed for Chapter 11 bankruptcy in April 2023 and ceased operations, with its assets subsequently acquired. Despite its closure, the company played a significant role in establishing the regulatory pathway and commercial model for digital therapeutics in healthcare.
Company description Pear Therapeutics official website
Primary marketMental Health & Digital Therapeutics
Commercial modelCommercial information available on request
Work at Pear Therapeutics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- chronic insomnia
- mental health disorders
- opioid use disorder
- substance use disorder
Who it serves
- Health Systems
- Payers
- Providers
Deployment & integration
Deployment information is currently being developed.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Filed for Chapter 11 bankruptcy in April 2023 and ceased operations; assets subsequently acquired
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Characteristics and Economic Outcomes of Treated and Untreated Patients Diagnosed with Opioid Use Disorder.Journal of pain & palliative care pharmacotherapy · Mar 1, 2026
Sleep-specific outcomes attributable to digitally delivered cognitive behavioral therapy for insomnia in adults with insomnia and depressive symptoms.Behavioral sleep medicine · Jan 1, 2024
Comparing substance use treatment initiation and retention between telehealth delivered during COVID-19 and in-person treatment pre-COVID-19.The American journal on addictions · May 1, 2023
A Prescription Digital Therapeutic to Support Unsupervised Buprenorphine Initiation for Patients With Opioid Use Disorder: Protocol for a Proof-of-Concept Study.JMIR research protocols · Jan 20, 2023
FDA regulations and prescription digital therapeutics: Evolving with the technologies they regulate.Frontiers in digital health · Jan 1, 2023
Evaluation of real-world outcomes associated with use of a prescription digital therapeutic to treat substance use disorders.The American journal on addictions · Jan 1, 2023
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
abstinence rates
improved outcomes in substance use disorder treatment
treatment adherence
increased engagement with therapeutic interventions
sleep quality
improvements in chronic insomnia symptoms
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Pear Therapeutics
Recent articles published on Pear Therapeutics's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Mental Health & Digital Therapeutics
Companies providing AI-powered mental health support, therapy platforms, mental wellness tracking, psychiatric care, digital therapeutics for mental health conditions, or AI-driven mental health screening and monitoring. Includes XR-based therapy, AI mental health screening infrastructure, and platforms supporting behavioral health for individuals and health systems.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.